Open AccessN 6 ‐methyladenosine Steers RNA Metabolism and Regulation in Cancer
Author(s) -
Dong Shenghua,
Wu Yutong,
Liu Yadi,
Weng Hengyou,
Huang Huilin
Publication year - 2021
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1002/cac2.12161
Subject(s) - epigenetics , rna , biology , carcinogenesis , rna methylation , cancer , rna splicing , methylation , rna interference , translation (biology) , cancer research , computational biology , gene , genetics , messenger rna , methyltransferase
As one of the most studied ribonucleic acid (RNA) modifications in eukaryotes, N 6 ‐methyladenosine (m 6 A) has been shown to play a predominant role in controlling gene expression and influence physiological and pathological processes such as oncogenesis and tumor progression. Writer and eraser proteins, acting opposite to deposit and remove m 6 A epigenetic marks, respectively, shape the cellular m 6 A landscape, while reader proteins preferentially recognize m 6 A modifications and mediate fate decision of the methylated RNAs, including RNA synthesis, splicing, exportation, translation, and stability. Therefore, RNA metabolism in cells is greatly influenced by these three classes of m 6 A regulators. Aberrant expression of m 6 A regulators has been widely reported in various types of cancer, leading to cancer initiation, progression, and drug resistance. The close links between m 6 A and cancer shed light on the potential use of m 6 A methylation and its regulators as prognostic biomarkers and drug targets for cancer therapy. Given the notable effects of m 6 A in reversing chemoresistance and enhancing immune therapy, it is a promising target for combined therapy. Herein, we summarize the recent discoveries on m 6 A and its regulators, emphasizing their influences on RNA metabolism, their dysregulation and impacts in diverse malignancies, and discuss the clinical implications of m 6 A modification in cancer.